L18: Pharmacogenetics and personalised medicine
Learning Objectives
Explain key terms used in pharmacogenomics;
Describe the effects of genetic polymorphism on drug metabolism and actions;
Appreciate the potential benefits of pharmacogenomics on healthcare and future drug development ;
Discuss the major obstacles for clinical application of pharmacogenomics
Pharmacogenetics and genetic variation
Pharmacogenetics: aiming to understand how the unique genetic composition of an individual can alter the pharmacokinetics and pharmacodynamic responses of that patien to a specific drug
Prodrug: becomes active after metabolism
Active drug: takes effect directly
Gene differences between individual humans
Mutations
frequency of variation at a particular locus in a population < 1%
point mutation
missense or nonsense silent mutation
insertion and deletion mutation
inversion
duplication
translocation
chromosomal aberration
often associated with rare diseases
cystic fibrosis
huntington’s disease
sickle cell anemia
Polymorphism
frequency of variation at a particular locus in a population > 1%
SNP is less likely to be the major cause of a disease
often no visible clinical impact
Single-nicleotude polymorphism (SNP)
linked SNPs (outside gene)
no effect in protein production or function
causative SNPs (in gene)
non-coding SNP: change amount of protein produced
coding SNP: change amino acid sequence → alter structure and function of protein
Other types of polymorphism
promoter polymorphisms
5’ and 3’ UTR polymorphism
Slice-Site polymorphism
insertion-deletion polymorphism (indels)
STRs polymorphism
Linkage Disequilibrium (LD) and Haplotype
allele: one of a pair of genes on a specific locus that control the same trait
haplotype: groups of alleles on a single chromosome that are closely linked→ inherited as a unit
LD: multiple SNPs that always appear together→ allele that are inherited as a unit: haplotype block
Polymophisms occur in gene encoding
Drug metabolising enzyme——cytochrom P-450 enzymes (CYP)
Characteristics
superfamily of monooxygenases
a large and diverse group of enzymes that catalyse the oxidation of organic substances
15 are known to be involved in drug metabolism
gene encoding of CYPs are highly polymorphic→ many isoenzyme
40% of drugs metabolism is carried out by CYP2C9, CYP2C19, CYP 2D6 enzyme
Effect of polymorphism
ultrarapid or rapid metaboliser
2 or multiple copies of functional allele and very high enzyme activity
lack of response (active drug)
adverse drug reaction (prodrug)
extensive or normal metaboliser
2 functional alleles and normal activity
expected response (active drug; prodrug)
intermediate metaboliser
either 1 functional and 1 defective allele or 2 partially defective alleles
→ reduced enzyme activity
exaggerated response (active drug)
reduced response (prodrug)
poor metaboliser
defective or deleted alleles and abolished enzyme activity
adverse drug reaction (active drug)
lack of response (prodrug)
AmpliChip CYP450 clinical test
genotype 29 known polymorphism in CYP2D6
including duplication and deletion
identify 2 major variants in CYP2C19
processes
PCR amplification
fragmentation or labelling of amplified products
hybridisation
staining
scanning od microarray
CYP2D6
Characteristics
mediate the most drug metabolism: 20-30%
polymorphism significantly affect the elimination of 50% of the currently-marketed drugs
Codeine (example of CYP2D6-mediated drug)
therapeutic use of codeine
opioid drug for analgesic, antitussive and anti-diarrhea
side effects: respiratory depression, constipation, sedation and addiction
pro-drug: needs to be metabolised to morphine
CYP2D6 polymorphism
poor metaboliser
unable to transform codeine to morphine
lack of pain relief → treatment failure
ultra-rapid metaboliser
convert codeine to morphine more quickly→ high exposure to morphine
breast feeding mom with CYP2D6 UM taking codeine→ risk health or even death to infants due yo morphine overdose via breast milk
CYP2C9
Characteristic
major role in oxidation of both xenobiotic (foreign) and endogenous (internal) compounds
make up ~18% of CYP450 proteins in liver
highly polymorphic with > 50 SNPs identified
major SNPs
CYP2C9*2: decrease activity by 30%
CYP2C9*3: decrease activity by 90%
warfarin (example of CYP2C9-mediated drug)
mechanism of warfarin
anti-coagulant drug for prevention of thrombosis
reduce body ability to make vitamin K, which helps synthesis of thrombocytes
inhibit vitamin K epoxide reductase complex 1 (VKORC1)
lower level of clotting protein makes blood cells less likely to clot
CYP2C9 enzyme metabolise warfarin
narrow therapeutic index (NTI)
effective daily dose: 0.5-80mg
CYP2C9 polymorphism
CYP2C9*2: reduces metabolism by 30%
CYP2C9×3: reduces metabolism by 90%
VKORC1 gene polymorphism (-1639 SNP)
G1639A → produce less VKORC1 enzyme
lower warfarin doses are required
Drug transportation / efflux
Adenosine triphosphate-binding cassette family (ABC)
Characteristics
present in cellular and intracellular membrane
import or remove substances form cells and tissue
ATP-dependent conformational change → substance transportation
ABCB1 transporter——P-glycoprotein (P-gp)
many drugs are transported across membranes
cytotoxic chemotherapeutic agents, protease inhibitors, anticonvulsants, antidepressants
expressed in intestine kidney liver, blood-brain barrier, spinal cord testes and placenta
drug efficiency
P-gp remove drug outside of cells in intestine
lower intestinal P-gp → increase bioavailability of drug
allow augmented drug effects and /or undesired effects due to prolonged drug exposure
polymorphism
2677G>A/T: exon 21→ change amino acid sequence
3435C>T: silent polymorphism in exon 26 → associate with ↓ expression of ABCB1
C1236T: silent polymorphism in exon 12
simvastatin
a lipid-lowering drug
response to this drug is affected by ABCB1 polymorphism
SLC transporter
types
OATs: organic anion transporter
OATPs: organic anion transporting polypeptides
OCTs: organic cation transporter
PepTs: peptide transport proteins
expressed in a variety of tissue.
liver, kidney, brain, intestine
Beta adrenergic receptors
ADRB2
important mediator of bronchodilation, ventilation and lipid metabolism
ADRB2 agonist: treat asthma
polymorphism
Arg16Gly, Gln27Glu, Thr164Ile
LD effect:
Arg16 is usually linked to Glu27
Gly16 is often linked with either Glu27 or Gln27
ADRB1
regulating heart rate contractility and renin release in kidney
common polymorphism
Ser49Gly
Arg389Gly
Ser49 and Arg389 shows enhanced receptor activity and increased response to beta blocker
Beta blocker
a class of drug target ADRB1
interfere with the binding to the receptor of epinephrine and other stress hormones
used for management of cardiac arrhythmias
examples
betaxolol
bisoprolol
metoprolol
Serotonin transporter protein (SERT)
44 bp insertion/deletion in promoter region → longer or shorter allele
drug response: longer allele > shorter
VNTR polymorphism: SERT has 3 alleles with 9, 10 and 12 copies of tandem repeat in the 2nd intron
drug responseL 12 copy > 9/10 copy